Compare Medtronic PLC (MDT) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Under Armour Inc Class A — how do they compare? Medtronic PLC trades at $88.79 (market cap $112.24B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Medtronic PLC is far larger — about 54.2× Under Armour Inc Class A's market cap, and Medtronic PLC pays a 3.28% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Under Armour Inc Class A for 18 Days on average.
| MDT | UA | |
|---|---|---|
Market Cap | $112.24B | $2.07B |
Volume | 105,663,236 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $7.88 |
52-Week Low | $73.75 | $3.96 |
Typical Hold Time | 63 Days | 18 Days |
Enterprise Value | $131.58B | $3.05B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
Under Armour (UA) trades at $4.81, up 2.34% with a bullish technical signal despite mixed fundamentals. The company reported declining revenues ($5.16B in 2025, $4.9B in 2026) and negative net income margins (-9.99%), though recent quarterly earnings showed beats in Q4 2025 and Q2 2026. Analyst sentiment is divided with 39.71% buy ratings, while cash flow trends show significant outflows (-$362M net in 2025).
The outlook remains challenging with revenue declines and profitability concerns, but the stock's low P/S ratio (0.41) may attract value investors. Key risks include sustained negative cash flow, competitive pressures, and execution on turnaround strategies. Near-term performance hinges on Q3 2026 earnings and guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
